Lari­mar Ther­a­peu­tics shares key bio­mark­er da­ta, aims for ac­cel­er­at­ed ap­proval for Friedre­ich’s atax­ia drug

Lari­mar Ther­a­peu­tics an­nounced Mon­day that its Friedre­ich’s atax­ia treat­ment in­creased me­di­an lev­els of a key pro­tein called fratax­in in a mid-stage study.

The biotech is in talks with the FDA to use fratax­in bio­mark­er da­ta to sup­port a po­ten­tial ac­cel­er­at­ed ap­proval sub­mis­sion in 2025, though its treat­ment is still un­der par­tial clin­i­cal hold.

In the Phase II study, pa­tients with Friedre­ich’s atax­ia re­ceived ei­ther 25 mg or 50 mg of nom­labo­fusp or place­bo. Their skin cells were biop­sied and buc­cal cells (the cells in­side the cheek) were swabbed to mea­sure lev­els of fratax­in. When peo­ple lack fratax­in, a mi­to­chon­dr­i­al pro­tein, it re­sults in mus­cle weak­ness and a loss of bal­ance and co­or­di­na­tion, among oth­er symp­toms.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA